In vitro activity of arbekacin against multidrug-resistant gram-negative bacilli.
Arbekacin
Enterobacterales
Multidrug-resistant gram-negative bacilli
Journal
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
ISSN: 1995-9133
Titre abrégé: J Microbiol Immunol Infect
Pays: England
ID NLM: 100956211
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
27
07
2020
revised:
13
08
2020
accepted:
25
08
2020
pubmed:
24
9
2020
medline:
22
1
2022
entrez:
23
9
2020
Statut:
ppublish
Résumé
Arbekacin is a broad-spectrum aminoglycoside with activity against some Gram-positive and Gram-negative bacteria. Arbekacin minimum inhibitory concentration (MIC) values were determined for 296 drug-resistant Gram-negative bacilli, and compared to previously determined plazomicin, amikacin, gentamicin, and tobramycin MIC values. The MIC values required to inhibit 50% and 90% of isolates (MIC Arbekacin showed similar MIC
Sections du résumé
BACKGROUND
BACKGROUND
Arbekacin is a broad-spectrum aminoglycoside with activity against some Gram-positive and Gram-negative bacteria.
METHODS
METHODS
Arbekacin minimum inhibitory concentration (MIC) values were determined for 296 drug-resistant Gram-negative bacilli, and compared to previously determined plazomicin, amikacin, gentamicin, and tobramycin MIC values.
RESULTS
RESULTS
The MIC values required to inhibit 50% and 90% of isolates (MIC
CONCLUSIONS
CONCLUSIONS
Arbekacin showed similar MIC
Identifiants
pubmed: 32962921
pii: S1684-1182(20)30216-4
doi: 10.1016/j.jmii.2020.08.018
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Dibekacin
45ZFO9E525
arbekacin
G7V6SLI20L
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1118-1121Informations de copyright
Copyright © 2020. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of competing interest RP reports grants from CD Diagnostics, Merck, Hutchison Biofilm Medical Solutions, Accelerate Diagnostics, Contrafect, TenNor Therapeutics Limited, and Shionogi. RP is a consultant to Curetis, Specific Technologies, Next Gen Diagnostics, PathoQuest, Selux Dx, and Qvella; monies are paid to Mayo Clinic. RP is a consultant to Netflix. In addition, RP has a patent on Bordetella pertussis/B. parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an antibiofilm substance issued. RP receives travel reimbursement from ASM and IDSA, an editor's stipend from IDSA, and honoraria from the NBME, Up-to-Date, and the Infectious Diseases Board Review Course. WAF is the chief executive officer and a shareholder at SelfCare UG (Haftungsbeschränkt), registered in Germany as HRB 760532.